text:
Seven Nights of DJs and Dancing
Thursday 29
Bikini Lounge: Scratchy Rekkid Night with DJ Shane Kennedy (various)
Coconut Club: DJ Coolstylz (Top 40, dance, hip-hop)
The Door: Pink Thursdays with DJ Astonish (hip-hop, Motown, Top 40)
Dance music
Dos Gringos - Tempe: DJ Steel (rock, '80s, old school, hip-hop)
Upcoming Events
Dierks Bentley
TicketsSat., Aug. 26, 7:30pm
Lord Huron
TicketsSat., Aug. 26, 8:00pm
Pat Benatar & Neil Giraldo
TicketsTue., Aug. 29, 7:30pm
Mary J. Blige
TicketsWed., Aug. 30, 8:00pm
Don't Look Back - Boston Tribute Band
TicketsFri., Sep. 1, 7:30pm
Glam: Under the Underground with DJVIRGO (EBM, industrial, synth pop)
Hollywood Alley: Blunt Club with Emerg McVay, Hyder, Pickster Uno, Tricky T, & DJ Tommy Blak (hip-hop, breaks)
Ippei: DJ Senbad (house)
J-Heads: Mic Fights with Bobkatt, DJ Kav, & guests (Top 40, hip-hop, R&B)
La Perla: DJ Big Latin (cumbia, old school, hip-hop, Top 40)
Rogue West: DJ Ryan (old school punk, reggae, jah, soul, funk)
Scorch Bar: DJ AL3 (Top 40)
SIX: Mint with DJ Fashen (classic rock, soul, old school funk, upscale hip-hop), & Kevin Brown (lounge, house)
Sky Lounge: Respect Is
Burning with DJ Tsunami (hip-hop, reggae, reggaeton)
Trax: Flirt Thursdays with DJ Soloman (hip-hop, rock, mash-ups)
Friday 30
Andersons Fifth Estate: Area 51 in the Elbow Room with DJ AKA (goth, industrial)
AZ 88: Mr. P-Body ('80s retro)
Baja Tillys: DJ Jerry (old school, R&B, cumbia, reggaeton)
Blue Note: DJ Propavillian (lounge, hip-hop, acid jazz)
Bobby Cs: Willie B (old school R&B)
Burn: French Kiss with William Fucking Reed, Kevin The Makeout Bandit, & DJ Filip (indie, electro, dance rock)
Buzz: Club Deez with DJ Knick Knack, & Da Nutz (hip-hop, R&B)
Club Blaze: DJs Smoove, Desert Dogg MC, J-U-Ice, Mark Mello, & guests (Top 40, hip-hop, R&B)
Club Tropicana: Club 95.1 live broadcast with DJs Shy & Leo Blaze (reggaeton, Latin pop, merengue, salsa)
Club Vibe: Sound Trip with DJ M2, & Karlie Hustle (classic hip-hop, funk, R&B soul, club bangers)
Coyote Hill: DJ G-zus (Top 40, hip-hop)
Devils Martini: DJ Sterling (Top 40, hip-hop)
The Door: DJ Mars (hip-hop, old school, Motown)
e4: "Touch" with DJ Michael Hagen in the Fire Room (hip-hop, mash-ups)
Glam: FauxShow with DJ Jared & Matt (high-energy indie rock)
Homme: StraightNoChaser's "one" with DJ Joe DiPadova & guests (deep house)
Jacks Place: Hip-Hop Pachanga with DJ 2Swift (hip-hop, R&B, reggaeton)
Library: DJ Diesel (hip-hop, rock, hop mash-ups)
The Lotus: Hip-Hop Fridays with DJs Rob Gee & Dan Tranzo (hip-hop, old school)
Macayos: DJs Big Latin & Richie Rich (Latin, hip-hop) Margarita Rocks: DJ Erotic (Top 40, hip-hop, rock)
Martini Ranch: DJ Randy (hip-hop, rock, dance)
Matador: Caliente Chica Fridays with DJs AL3, Deuce, & The Manic Hispanic (reggaeton, hip-hop, old school, cumbia)
Myst: House 7340 with Jon Bishop (house)
Next: Grown & Sexy Fridays with DJs Robbie Rob & Illmatic (hip-hop, R&B, dancehall, neo-soul)
Paco Paco: DJ Jeremy (Latin, hip-hop, reggaeton)
Palazzo: Tranzylvania (EBM, gothic, industrial)
Redfish: DJ Benny Hill (hip-hop, dance)
Skybar: William Fucking Reed (lounge, downtempo, electro)
Sol y Sombra: DJ Pete Salaz (house)
Tapas: Culture Lounge with DJ Seduce (jazz, downtempo, soul, electronica)
Zuma: DJ Sean Morley (hip-hop, rock, mash-ups)
Saturday 31
Acme Bar: DJ Switch (Top 40, rock)
AZ 88: DJ Brazilia (Brazilian house, super soul)
Cash Inn: DJ Kat (country)
Chilly Bombers: DJ Statik (rock, hip-hop, dance)
Club Blaze: DJs Smoove, Desert Dogg MC, Mark Mello, & guests (Top 40, hip-hop, R&B, Latin)
Club Central: DJs Ernie G. (R&B), DJ Luis (salsa)
Coconut Club: DJ Coolstylz (Top 40, dance, hip-hop)
Club Reventon: Noche Latina with DJs Shy & Big Latin (merengue, reggaeton, cumbia, hip-hop)
Dos Gringos - Tempe: DJ Pulse (rock, '80s, old school, hip-hop)
e4: DJ Kevin Brown in the Liquid Room (house), & DJ D-Trip in the Fire Room (hip-hop, pop, mash-ups)
E-Lounge: DJ Statik (hip-hop, rock, house)
Garcias: DJ Jim (salsa, cumbia, hip-hop, R&B)
Glam: Beat Surrender with DJ Anthony (indie rock, hip-hop)
Graham Central Station: DJs Gonzo (retro), & Cowboy Craig (country)
Hidden House: The Shop with Al Page & guests (underground hip-hop, dancehall, old school)
Hurricane Bay: DJ MD (Top 40, retro)
Phase 54: DJ Moe (Top 40)
Pussycat Lounge: D-JR (Top 40, hip-hop, rock)
Q Lounge: DJ Greggy D (Top 40, hip-hop)
Rogue East: Shake! with William Fucking Reed, Jay Wiggins, & DJ P-Body (indie, Britpop, dance rock)
Tavern on Mill: DJ Adrenaline (Top 40, hip-hop)
Uno Mas: DJ Paul (Latin vibe)
Way Cool: Djentrification (various)
Sunday 1
AZ 88: Mr. P-Body (indie, vintage)
Burn: Confession with DJs Pete Salaz, Joe DiPadova, & Senbad (deep house)
Camus: Are You In? with guest DJs (various)
The Door: Brown Sugar Sundays with DJs M2 & Flava (hip-hop, reggae, funk)
Karamba: Kaliente Sunday with DJ Miguel (salsa, merengue, cumbia, Latin pop)
Paper Heart: Head Space with DJs Hahn, Nick Synergy, Dionysos Pan Eros, & Moksha Mind (downtempo, dub, psychedelica)
Yucca Tap Room: DJs Dana, Bindlestiff Matt, & more (various)
Monday 2
Cherry Lounge: DJ J. Alan (rock, '80s, old school, hip-hop)
Coach & Willies: Koncrete Jungle (deep house, jungle, drum 'n' bass)
Glam: Boom Box Crew Spinning (hip-hop, funk, soul, dubstep)
Hidden House: Foreign Affair with DJs Delikacy & Extra E (downtempo beats)
La Rouge : Pete Salaz (house)
Trax: Shimmy with DJs Hyder, Diosa, & guests (neo-soul, electro, downtempo, liquid funk, trip-hop)
Zuma: Toxic Mondays with DJ Circle (Top 40, hip-hop)
Tuesday 3
Bikini Lounge: 602esdays with Brandon Still, & guests (various)
Cherry Lounge: DJ Tranzl8tr (rock, '80s, old school, hip-hop)
Chilly Bombers: DJ Statik (rock, hip-hop, dance)
Club Central: DJ Ernie G. (hip-hop, R&B)
Coyote Hill: DJ G-zus (Top 40, hip-hop)
DrinX: DJ Soloman (hip-hop, house, breaks)
e4: "Ultra" with DJ Kevin Brown (house)
Glam: DJ Ramone (goth, industrial)
La Perla: Hip-Hop Tuesdays with DJs Big Latin, & Villin (hip-hop)
Q Lounge: DJ D-Trip & Greggy D (Top 40, hip-hop)
Stray Cat: Take Me Back Tuesdays with DJs Senior Phat E, Reflekshin, Area 4, T3PO, & guests (old school hip-hop, funk, soul)
Wednesday 4
George & Dragon: Style Council with William Fucking Reed, Scooter Paul, & guests (mod, Britpop, northern soul, two tone)
Hurricane Bay: DJ MD (Top 40, retro)
Karamba: Retro Wednesdays (retro Latin dance, Top 40, hip-hop, reggaeton)
The Lotus: Hispanic Night with DJ Que (reggaeton)
Redfish: DJ Benny Hill (hip-hop, dance)
Shaynas: DJ ES (hip-hop)
SIX: La Femme with DJ Mikyl (house, Top 40, hip-hop)
Stray Cat: BANNED in Tempe with DJ Johnny Volume, & guests (punk, reggae, hardcore, garage)
Suede: DJs Circle (Top 40, dance, hip-hop)
Tavern on Mill: DJ Adrenaline (Top 40, hip-hop)
Willow House: Djentrification & Peso One (various rarities)
Zuma: DJ Suga Bear (hip-hop)
Get the ICYMI: Today's Top Stories Newsletter Our daily newsletter delivers quick clicks to keep you in the know
Catch up on the day's news and stay informed with our daily digest of the most popular news, music, food and arts stories in Phoenix, delivered to your inbox Monday through Friday.
Recommended for You
Powered by SailThru
Upcoming Events
Foreigner & Cheap Trick
TicketsThu., Aug. 24, 7:00pm
The Australian Pink Floyd
TicketsThu., Aug. 24, 8:00pm
TicketsFri., Aug. 25, 7:00pm
TicketsSun., Aug. 6, 8:00pmpowered by goldstar
Sponsor Content


text:
Hatts grinds to halt as administrators called
A family owned bus and coach company that transports war veterans to the D-day landing sites in France fell into administration yesterday, sparking almost 90 job losses and leaving about 1,000 ticket holders in the lurch.
Staff at Hatts Coaches, which has been owned by the Hillier family since 1928, were told that the company had brought in administrators at FRP Advisory after running out of cash.
Hatts, which has sites in Salisbury, Worton and Foxham in Wiltshire, had been operating day trips to destinations in Britain and is popular among pensioners. Its fourth-generation family owners have been struggling for weeks to refinance the business.
It operated a fleet of 90 buses and coaches and provided the coach service for Bath Rugby team, a park-and-ride…

subset: commoncrawl


text:
Wilfrid Scawen Blunt
Wilfrid Scawen Blunt (1840 - 1922 / England)
» Click to list general statistics » OR, select a date :
A New Pilgrimage: Sonnet X
Whence is our pleasure in things beautiful?
We are not born with it, we do not know,
By instinct of the eye or natural rule,
read more >>
- Hits: Number of visitors who read the poem on the given date.
- Posts: Number of visitors who posted the poem to a friend (via e-mail) on the given date.
- Dates that have "0" hits may not be shown on the list.
- Dates, poems and poets that have "0" hits may not be shown on the list. Statistics are generated daily.


text:
The mabinogion
MATH the son of Mathonwy was lord over
Gwynedd, and Pryderi the
son of Pwyll was lord over the one-and-twenty Cantrevs of the South; and these
were the seven Cantrevs of Dyved, and the seven Cantrevs of Morganwc, the four
Cantrevs of Ceredigiawn, and the three of Ystrad Tywi.
"The three sons of Gilvaethwy the false,Then he struck the two with his magic wand, and they resumed their own nature. "Oh men," said he, "for the wrong that ye did unto me sufficient has been your punishment and your dishonour. Prepare now precious ointment for these men, and wash their heads, and equip them." And this was done.
And after they were equipped, they came unto him. "Oh men," said he, "you have obtained peace, and you shall likewise have friendship. Give your counsel unto me, what maiden I shall seek." "Lord," said Gwydion the son of Don, "it is easy to give thee counsel; seek Arianrod, the daughter of Don, thy niece, thy sister's daughter."
And they brought her unto him, and the maiden came in. "Ha, damsel," said he, "art thou the maiden?" "I know not, lord, other than that I am." Then he took up his magic wand, and bent it. "Step over this," said he, "and I shall know if thou art the maiden." Then stepped she over the magic wand, and there appeared forthwith a fine chubby yellow-haired boy. And at the crying out of the boy, she went towards the door. And thereupon some small form was seen; but before any one could get a second glimpse of it, Gwydion had taken it, and had flang a scarf of velvet around it and hidden it. Now the place where he hid it was the bottom of a chest at the foot of his bed.
"Verily," said Math the son of Mathonwy, concerning the fine yellow-haired boy, "I will cause this one to be baptized, and Dylan is the name I will give him."
So they had the boy baptized, and as they baptized him he plunged into the sea. And immediately when he was in the sea, he took its nature, and swam as well as the best fish that was therein. And for that reason was he called Dylan, the son of the Wave. Beneath him no wave ever broke. And the blow whereby he came to his death, was struck by his uncle Govannion. The third fatal blow was it called.
As Gwydion lay one morning on his bed awake, he heard a cry in the chest at his feet; and though it was not loud, it was such that he could hear it. Then he arose in haste, and opened the chest: and when he opened it, he beheld an infant boy stretching out his arms from the folds of the scarf, and casting it aside. And he took up the boy in his arms, and carried him to a place where he knew there was a woman that could nurse him. And he agreed with the woman that she should take charge of the boy. And that year he was nursed.
And at the end of the year he seemed by his size as though he were two years old. And the second year he was a big child, and able to go to the Court by himself. And when he came to the Court, Gwydion noticed him, and the boy became familiar with him, and loved him better than any one else. Then was the boy reared at the Court until he was four years old, when he was as big as though he had been eight.
And one day Gwydion walked forth, and the boy followed him, and he went to the Castle of Arianrod, having the boy with him; and when he came into the Court, Arianrod arose to meet him, and greeted him and bade him welcome. "Heaven prosper thee," said he. "Who is the boy that followeth thee?" she asked. "This youth, he is thy son," he answered. "Alas," said she, "what has come unto thee that thou shouldst shame me thus, wherefore dost thou seek my dishonour, and retain it so long as this?" "Unless thou suffer dishonour greater than that of my bringing up such a boy as this, small will be thy disgrace." "What is the name of the boy?" said she. "Verily," he replied, "he has not yet a name." "Well," she said, "I lay this destiny upon him, that he shall never have a name until he receives one from me." "Heaven bears me witness," answered he, "that thou art a wicked woman. But the boy shall have a name how displeasing soever it may be unto thee. As for thee, that which afflicts thee is that thou art no longer called a damsel." And thereupon he went forth in wrath, and returned to Caer Dathyl, and there he tarried that night.
And the next day he arose and took the boy with him, and went to walk on the sea shore between that place and Aber Menei. And there he saw some sedges and sea weed, and he turned them into a boat. And out of dry sticks and sedges he made some Cordovan leather, and a great deal thereof, and be coloured it in such a manner that no one ever saw leather more beautiful than it. Then he made a sail to the boat, and he and the boy went in it to the port of the castle of Arianrod. And he began forming shoes and stitching them, until he was observed from the castle. And when he knew that they of the castle were observing him, he disguised his aspect, and put another semblance upon himself, and upon the boy, so that they might not be known. " What men are those in yonder boat?" said Arianrod. "They are cordwainers," answered they. "Go and see what kind of leather they have, and what kind of work they can do."
So they came unto them. And when they came he was colouring some Cordovan leather, and gilding it. And the messengers came and told her this. "Well," said she, "take the measure of my foot, and desire the cordwainer to make shoes for me." So he made the shoes for her, yet not according to the measure, but larger. The shoes then were brought unto her, and behold they were too large. "These are too large," said she, "but he shall receive their value. Let him also make some that are smaller than they." Then he made her others that were much smaller than her foot, and sent them unto her. "Tell him that these will not go on my feet," said she. And they told him this. "Verily," said he, "I will not make her any shoes, unless I see her foot." And this was told unto her. "Truly," she answered, "I will go unto him."
So she went down to the boat, and when she came there, he was shaping shoes and the boy stitching them. "Ah lady," said he, "good day to thee." "Heaven prosper thee," said she. "I marvel that then canst not manage to make shoes according to a measure." "I could not," he replied, "but now I shall be able."
Thereupon behold a wren stood upon the deck of the boat, and the boy shot at it, and hit it in the leg between the sinew and the bone. Then she smiled. "Verily," said she, "with a steady hand did the lion aim at it." "Heaven reward thee not, but now has he got a name. And a good enough name it is. Llew Llaw Gyffes be he called henceforth."
Then the work disappeared in sea weed and sedges, and he went on with it no further. And for that reason was he called the third Gold-shoemaker. "Of a truth," said she, thou wilt not thrive the better for doing evil unto me." "I have done thee no evil yet," said he. Then he restored the boy to his own form. "Well," said she, "I will lay a destiny upon this boy, that he shall never have arms and armour until I invest him with them." "By Heaven," said he, "Iet thy malice be what it may, he shall have arms."
Then they went towards Dinas Dinllev, and there he brought up Llew Llaw Gyffes, until he could manage any horse, and he was perfect in features, and strength, and stature. And then Gwydion saw that he languished through the want of horses, and arms. And he called him unto him. "Ah, youth," said he, "we will go to-morrow on an errand together. Be therefore more cheerful than thou art." "That I will," said the youth.
Next morning, at the dawn of day, they arose. And they took way along the sea coast, up towards Bryn Aryen. And at the top of Cevn Clydno they equipped themselves with horses, and went towards the Castle of Arianrod. And they changed their form, and pricked towards the gate in the semblance of two youths, but the aspect of Gwydion was more staid than that of the other. "Porter," said he, "go thou in and say that there are here bards from Glamorgan." And the porter went in. "The welcome of Heaven be unto them, let them in," said Arianrod.
With great joy were they greeted. And the hall was arranged, and they went to meat. When meat was ended, Arianrod discoursed with Gwydion of tales and stories. Now Gwydion was an excellent teller of tales. And when it was time to leave off feasting, a chamber was prepared for them, and they went to rest.
In the early twilight Gwydion arose, and he called unto him his magic and his power. And by the time that the day dawned, there resounded through the land uproar, and
trumpets, and shouts. When it was now day, they heard a knocking at the door of the chamber, and therewith Arianrod asking that it might be opened. Up rose the youth and opened unto her, and she entered and a maiden with her. "Ah, good men," she said, "in evil plight are we." "Yes, truly," said Gwydion, " we have heard trumpets, and shouts; what thinkest thou that they may mean?" "Verily," said she, "we cannot see the colour of the ocean by reason of all the ships, side by side. And they are making for the land with all the speed they can. And what can we do?" said she. "Lady," said Gwydion, "there is none other counsel than to close the castle upon us, and to defend it as best we may." "Truly," said she, "may Heaven reward you. And do you defend it. And here may you have plenty of arms." And thereupon went she forth for the arms, and behold she returned, and two maidens, and suits of armour for two men, with her. "Lady," said he, " do thou accoutre this stripling, and I will arm myself with the help of thy maidens. Lo, I hear the tumult of the men approaching." "I will do so, gladly." So she armed him fully, and that right cheerfully. Hast thou finished arming the youth?" said he. "I have finished," she answered. "I likewise have finished," said Gwydion. "Let us now take off our arms, we have no need of them." "Wherefore?" said she. "Here is the army around the house." "Oh, lady, there is here no army." "Oh," cried she, "whence then was this tumult?" "The tumult was but to break thy prophecy and to obtain arms for thy son. And now has he got arms without any thanks unto thee." "By Heaven," said Arianrod, "thou art a wicked man. Many a youth might have lost his life through the uproar thou hast caused in this Cantrev to-day. Now will I lay a destiny upon this youth," she said, "that he shall never have a wife of the race that now inhabits this earth." "Verily," said he, "thou wast ever a malicious woman, and no one ought to support thee. A wife shall he have notwithstanding."
They went thereupon unto Math the son Mathonwy, and complained unto him most bitterly of Arianrod. Gwydion showed him also how he had procured arms for the youth. "Well," said Math, "we will seek, I and thou, by charms and illusion, to form a wife for him out of flowers. He has now come to man's stature, and he is the comeliest youth that was ever beheld." So they took the blossoms of the oak, and the blossoms of the broom, and the blossoms of the meadowsweet, and produced from them a maiden, the fairest and most graceful that man ever saw. And they baptized her, and gave her the name of Blodeuwedd.
After she had become his bride, and they had feasted, said Gwydion, "It is not easy for a man to maintain himself without possessions." "Of a truth," said Math, "I will give the young man the best Cantrev to hold." "Lord," said he, "what Cantrev is that?" "The Cantrev of Dinodig," he answered. Now it is called at this day Eivionydd and Ardudwy. And the place in the Cantrev where he dwelt, was a palace of his in a spot called Mur y Castell, on the confines of Ardudwy. There dwelt he and reigned, and both he and his sway were beloved by all.
One day he went forth to Caer Dathyl, to visit Math the son of Mathonwy. And on the day that he set out for Caer Dathyl, Blodeuwedd walked in the court. And she heard the sound of a horn. And after the sound of the horn, behold a tired stag went by, with dogs and huntsmen following it. And after the dogs and the huntsmen there came a crowd of men on foot. "Send a youth," said she, " to ask who yonder host may be." So a youth went, and inquired who they were. "Gronw Pebyr is this, the lord of Penllynn," said they. And thus the youth told her.
Gronw Pebyr pursued the stag, and by the river Cynvael he overtook the stag and killed it. And what with flaying the stag and baiting his dogs, he was there until the night began to close in upon him. And as the day departed and the night drew near, he came to the gate of the Court. "Verily," said Blodeuwedd, "the Chieftain will speak ill of us if we let him at this hour depart to another land without inviting him in." "Yes, truly, lady," said they, "it will be most fitting to invite him."
Then went messengers to meet him and bid him in. And he accepted her bidding gladly, and came to the Court, and Blodeuwedd went to meet him and greeted him, and bade him welcome. "Lady," said he, "Heaven repay thee thy kindness."
When the had disaccoutred themselves, they went to sit down. And Blodeuwedd looked upon him, and from the moment that she looked on him she became filled with his love. And he gazed on her, and the same thought came unto him as unto her, so that he could not conceal from her that he loved her, but he declared unto her that he did so. Thereupon she was very joyful. And all their discourse that night was concerning the affection and love which they felt one for the other, and which in no longer space than one evening had arisen. And that evening passed they in each other's company.
The next day he sought to depart. But she said, "I pray thee go not from me to-day." And that night he tarried also. And that night they consulted by what means they might always be together. "There is none other counsel," said he, "but that thou strive to learn from Llew Llaw Gyffes in what manner he will meet his death. And this must thou do under the semblance of solicitude concerning him."
The next day Gronw sought to depart. "Verily," said she, "I will counsel thee not to go from me to-day." "At thy instance will I not go," said he, "albeit, I must say, there is danger that the chief who owns the palace may return home." "To-morrow," answered she, "will I indeed permit thee to go forth."
The next day he sought to go, and she hindered him not. "Be mindful," said Gronw, "of what I have said unto thee, and converse with him fully, and that under the guise of the dalliance of love, and find out by what means he may come to his death."
That night Llew Llaw Gyffes returned to his home. And the day they spent in discourse, and minstrelsy, and feasting. And at night they went to rest, and he spoke to Blodeuwedd once, and he spoke to her a second time. But, for all this, he could not get from her one word. "What aileth thee," said he, " art thou well?" "I was thinking," said she, "of that which thou didst never think of concerning me; for I was sorrowful as to thy death, lest thou shouldst go sooner than I." "Heaven reward thy care for me," said he, "but until Heaven take me I shall not easily be slain." "For the sake of Heaven, and for mine, show me how thou mightest be slain. My memory in guarding is better than thine." "I will tell thee gladly," said he. "Not easily can I be slain, except by a wound. And the spear wherewith I am struck must be a year in the forming. And nothing must be done towards it except during the sacrifice on Sundays." "Is this certain?" asked she. "It is in truth," he answered. "And I cannot be slain within a house, nor without. I cannot be slain on horseback nor on foot." "Verily," said she, "in what manner then canst thou be slain?" "I will tell thee," said he. "By making a bath for me by the side of a river, and by putting a roof over the cauldron, and thatching it well and tightly, and bringing a buck, and putting it beside the cauldron. Then if I place one foot on the buck's back, and the other on the edge of the cauldron, whosoever strikes me thus will cause my death." "Well," said she, "I thank Heaven that it will be easy to avoid this."
No sooner had she held this discourse than she sent to Gronw Pebyr. Gronw toiled at making the spear, and that day twelvemonth it was ready. And that very day he caused her to be informed thereof.
"Lord," said Blodeuwedd unto Llew, "I have been thinking how it is possible that what thou didst tell me formerly can be true; wilt thou show me in what manner thou couldst stand at once upon the edge of a cauldron and upon a buck, if I prepare the bath for thee?" "I will show thee," said he.
Then she sent unto Gronw, and bade him be in ambush on the hill which is now called Bryn Kyvergyr, on the bank of the river Cynvael. She caused also to be collected all the goats that were in the Cantrev, and had them brought to the other side of the river, opposite Bryn Kyvergyr.
And the next day she spoke thus. "Lord," said she, "I have caused the roof and the bath to be prepared, and lo! they are ready." "Well," said Llew, "we will go gladly to look at them."
The day after they came and looked at the bath. "Wilt thou go into the bath, lord?" said she. "Willingly will I go in," he answered. So into the bath he went, and he anointed himself. "Lord," said she, "behold the animals which thou didst speak of as being called bucks." "Well," said he, cause one of them to be caught and brought here." And the buck was brought. Then Llew rose out of the bath, and put on his trowsers, and he placed one foot on the edge of the bath and the other on the buck's back.
Thereupon Gronw rose up from the hill which is called Bryn Cyvergyr, and he rested on one knee, and flung the poisoned dart and struck him on the side, so that the shaft started out, but the head of the dart remained in. Then he flew up in the form of an eagle and gave a fearful scream. And thenceforth was he no more seen.
As soon as he departed Gronw and Blodeuwedd went together unto the palace that night. And the next day Gronw arose and took possession of Ardudwy. And after he had overcome the land, he ruled over it, so that Ardudwy and Penllyn were both under his sway.
Then these tidings reached Math the son of Mathonwy. And heaviness and grief came upon Math, and much more upon Gwydion than upon him. "Lord," said Gwydion, "I shall never rest until I have tidings of my nephew." "Verily," said Math, "may Heaven be thy strength." Then Gwydion set forth and began to go forward. And he went through Gwynedd and Powys to the confines. And when he had done so, he went into Arvon, and came to the house of a vassal, in Maenawr Penardd. And he alighted at the house, and stayed there that night. The man of the house and his household came in, and last of all came there the swineherd. Said the man of the house to the swineherd, "Well, youth, hath thy sow come in to-night?" She hath," said he, "and is this instant returned to the pigs." "Where doth this sow go to?" said Gwydion. "Every day, when the sty is opened, she goeth forth and none can catch sight of her, neither is it known whither she goeth more than if she sank into the earth." "Wilt thou grant unto me," said Gwydion, "not to open the sty until I am beside the sty with thee." "This will I do, right gladly," he answered.
That night they went to rest; and as soon as the swineherd saw the light of day, he awoke Gwydion. And Gwydion arose and dressed himself, and went with the swineherd, and stood beside the sty. Then the swineherd opened the sty. And as soon as he opened it, behold she leaped forth, and set off with great speed. And Gwydion followed her, and she went against the course of a river, and made for a brook, which is, now called Nant y Llew. And there she halted and began feeding. And Gwydion came under the tree, and looked what it might be that the sow was feeding on. And he saw that she was eating putrid flesh and vermin. Then looked he up to the top of the tree, and as he looked he beheld on the top of the tree an eagle, and when the eagle shook itself, there fell vermin and putrid flesh from off it, and these the sow devoured. And it seemed to him that the eagle was Llew. And he sang an Englyn: -
"Oak that grows between the two banks;
"Upon this the eagle came down until he reached the centre of the tree. And Gwydion sang another Englyn:-
"Oak that grows in upland ground,
Then the eagle came down until he was on the lowest branch of the tree, and thereupon this Englyn did Gwydion sing:-
"Oak that grows beneath the steep;
And the eagle came down upon Gwydion's
knee. And Gwydion struck him with his magic wand, so that he returned to his own
form. No one ever saw a more piteous sight, for he was nothing but skin and


text:
1 Recommendation
SpiritMama's recommendation
Sarah has a broken heart, her lover has left her with nothing but a box of memories. Sarah comes with her box of memories, containing a photograph of her lost love, some dried flowers from their first date, a letter from him, and a tiny white ring box.
My Collections:


text:
Artist Statement
Over the years I have focused on developing a visual language consisting of strong iconography, and mark making, wherein, I would have a library of messaging of which to utilize. This growing library of icons serves as my own typeset of sorts, and enables me to explore multiple approaches to creating cohesive and non-cohesive narratives, landscapes, and stylistic experimentations through varying degrees of intensity, color and composition.
Matthew Curry is an Illustrator, Graphic Designer and Painter that lives and works from his studio in the Washington DC metro area.


text:
Sign up to StockTwits to save a watchlist for easy access to your favorite stocks
Basically a noob. Trying my best to learn from everyone.
Connect and collaborate with traders and investors like @juanjoarguello9
StockTwits is 100% Free!
Create your own stock
portfolio watchlist
Full access to all ticker
Streams and data tools
Follow and learn from your
favorite market leaders
Post your own trading
ideas, predictions &


text:
Nikolai Rimsky-Korsakov was born in 1844 in Tikhvin, a village east of St. Petersburg, Russia. Though Nikolai showed a talent for music at an early age, he pursued an education at the School for Mathematical and Navigational Sciences in St. Petersburg and later joined the Imperial Russian Navy. It was not until he met Mily Balakirev in 1861 that he decided to concentrate on developing his musical skills. When Rimsky-Korsakov was not at sea, Balakirev encouraged and taught him how to compose music. It also was through Balakirev that Rimsky-Korsakov met four other composers who later became known as the The Five. Read more...
Scheherezade (Theme) by Nikolai Rimsky-Korsakov for Intermediate/Level 3 Piano Solo
Preview and Print
Preview and print this free printable sheet music by clicking on the purple button above the music.
Listen to this sheet music arrangement by clicking on the green button.
Trouble opening PDF? You may need to download or update Acrobat Reader first. Click the purple button to download reader.
Sign up to receive the MakingMusicFun.net Newsletter so you don't miss a thing!


text:
By now, if you are a fan of NASCAR, you are fully up to date on the latest tangle between Kevin Harvick and Kyle Busch. Two drivers who are intense, passionate about winning and thrive on controversy. Don't let them tell you otherwise. But there are other drivers who are rarely in the limelight except for winning races. Boys that don't have at it very often.
NASCAR's Quiet Men: Five drivers who don't thrive on controversy
Current Status: Blessed (1)
Seeded on Thu May 12, 2011 11:15 AM
keyboard shortcuts: V vote up article J next comment K previous comment


text:
It only takes a minute to get started. Fill out our simple sign up form and login to the site.
This step is discretionary but will drastically increase your chances of people actually reading your profile and contacting you. Introduce yourself, your hobbies and attach any nice photographs of yourself.
Utilise our website's advanced search to discover over 60s members who fulfill your criteria. Or just scan through listings and discover singles that take your fancy.
Located someone who looks appealing? Drop them a line or just a wink and see if anything develops. With a little luck you'll be on your way to finding your perfect match.
It's quick and simple


text:
FTP Connection – How to FTP to your Account
To establish an FTP connection and access your account, there are several things you need to know:
- The FTP server hostname - usually, this is your domain name. In addition, you can access your account directly via your server IP (this eliminates domain resolving issues).
- Your FTP login details - if your account is hosted in a company, that uses cPanel like SiteGround, you can create FTP users, assign folders to them and set their passwords via the FTP Users tool.
- FTP connection software - you need either a browser that supports FTP connection, or a specialised FTP client in order to access your account. Check out our article on how to establish an FTP connection using an FTP client for more information on that matter.
FTP is easy to set up and work with when you have the right host to support you. Check out what SiteGround's FTP hosting offers and sign up for our services so you could rely on expert FTP assistance!


text:
shop by Brand
shop by Theme
Newsletter Sign Up
shop by brand
shop by theme
"I just wanted you to know that when the two pieces of flannel I recently ordered arrived, I was thrilled with the quality and everything else about them!"
I received my order today and wanted to tell you I love this fabric!! The quality is awesome. The service I received from you was wonderful as well. What an awesome company - I will be ordering again soon!"
"I wanted to let you know how much I enjoyed your store. WOW is all I can say! Your staff was over the top helpful and friendly. I hope you all put your feet up for awhile when it was over."
It is a light weight, but exceptionally strong, silky rayon thread. It is colorfast, both washable and dry cleanable. It is recommended that no bleach or whitening agents be used when laundering. While it is a utilitarian weight that works very well in all decorative applications, it is the preferred thread for "free-motion" machine embroidery as well as computerized embroidery. Most computer embroidery designs are digitized for Sulky 40 wt. Rayon Thread.
Add To Cart
Copyright - Hancock's of Paducah. All Rights Reserved.


text:
Editors' Note: Download.com has chosen not to provide a direct-download link for this product and offers this page for informational purposes only.
Sponsored Products
|MP3 & Audio Software
|Media Players
Publisher's Description+
Toast with Jam 6 combines the entire award-winning Toast 6 Titanium suite with a rich array of audio software for musicians and music lovers to create superior sounding CDs and DVDs.
Toast with Jam 6 includes:
- Toast 6 Titanium suite - includes Toast, CD Spin Doctor, Motion Pictures, Discus RE, Deja Vu backup
- Jam 6 - CD mixing/mastering software
- Dolby Digital sound - for DVD video and music albums
- Peak 4 Express - stereo editor
Ideal for use with home theaters and in-car DVD players, the new DVD Music Album creates audio DVDs with over 36 hours of Dolby Digital quality music complete with on-screen menus, auto-play navigation, song information, and even album artwork.
Dolby Digital, the Hollywood standard, provides the added benefit of adding over two hours of video to DVDs while maintaining video quality and audio fidelity.
What's new in this version:
Includes all previous Jam 6 updates and:
- Following discussions with Apple, this version will no longer allow customers to create audio CDs or export audio to their hard drive using purchased iTunes music store content.
- Resolves an issue where certain ISRC codes could not be entered.
- Resolves an issue where Jam fails to launch when audio output is set to 96 kHz.
- Resolves an issue with images failing to be mounted or unmounted on Mac OS 10.4 (T... See all new features »


text:
Casa de Colour- 3/4" x 2-1/4" Rustic Pewter Maple Stained Solid Hardwood Flooring-
Live comfortably in your home and increase its value with the rich shades of the Casa de Colour Collection by Dura-Wood.
About Casa de Colour:The desire to return to a more relaxed way of living has inspired many to embrace the beauty of their surroundings. It is this same desire that is the inspiration behind Dura-Wood's line of stained pre-finished floors, Casa de Colour Collection. These solid hardwood floors come with a 30 year warranty to ensure you'll enjoy your floors for years to come.
We caught up with real Lumber Liquidators' customers who volunteered to discuss their floor shopping, buying and installation experiences. In no way did these customers receive compensation for their kind words. (They're speaking straight from the heart.)
Questions?Please allow us to assist you with any questions and/or concerns.Click here to go to Flooring 101, or call 1-800-HARDWOOD to speak to one of our flooring experts.We will be glad to help you select the appropriate products for your commercial or residential remodeling project.
(based on 1 review)
Ratings Distribution
5 Stars
4 Stars
3 Stars
2 Stars
1 Stars
Reviewed by 1 customer
Displaying review 1
Back to top
(2 of 2 customers found this review helpful)
Not Rustic At All
By Jay
from Fort Worth, TX
Best Uses
Product was delivered with no stain or finish on the micro bevel. Since entire shipment was affected, had to return. Most likely a systemic issue with the product line. Name and picture are misleading. Picture leads one to believe there is a large amount of variation (aka Rustic) to the appearance. There was nothing rustic about the design as it was all pewter (grey).
Service and delivery comments:
Staff was very helpful in handling my return.
Bottom Line No, I would not recommend this to a friend
Was this review helpful? Yes / No
- You may also flag this review
NO formaldehyde is used in the manufacturingor construction of this flooring.


text:
About the Book
There is so much visual information for us to process that it's easy to walk past the tiniest things without noticing them. When we do spot a hoverfly, a damselfly, or a glistening dewdrop it is difficult to appreciate the level of detail and beauty that exists in these things - the human eye is not really designed for that; we live in a much bigger world.
Macro photography changes all this and, although it is a technically challenging discipline, it is so absorbing that it is easy to become lost for hours at a time inside the incredible world that exists beyond our normal view.
"beyond our normal view - vol. 2" is a collection of 100 macro photographs captured during 2009. The photographs in this 114-page book are arranged in six sections: hymenoptera (bees and wasps), diptera (flies and other two-winged insects), odonata (damselflies and dragonflies), other insects (shield bugs, butterflies, moths, planthoppers, beetles, etc.), araneae (spiders) and flora (plants).
If you would like more information, or if have any questions about this publication, you can get in touch with me through my website: www.robault.co.uk.
Volume 1 of "beyond our normal view": http://www.blurb.com/bookstore/detail/569146.
Volume 3 of "beyond our normal view": http://www.blurb.com/bookstore/detail/2054783
Thank you for looking,
Features & Details
- Category Arts & Photography
Standard Landscape, 10×8 in, 25×20 cm
114 Pages
- Publish Date Mar 08, 2010
- Tags macro photography, nature photography, macro, close-up, closeup, insects, photography, wildlife, nature, damselflies, bees, flies, fly, damselfly, dragonfly, wasp, beetle, photos
About the Creator
Rob Ault is a musician by profession, a macro photographer, and lives in Woking, in the UK.
Log in or create an account to post a comment.
1 Comments
Kitty Kono Your photographs are marvelous. So beautiful. I too love macro photography. Your damselflies and dragonflies are exquisite.
Kitty Kono


text:
Video of Samuel L. Jackson Scolding Reporter for Mistaking Him for Lawrence Fishburne
You ever watch an interview so awkward you wish you could just help the reporter hide?
One reporter probably wishes he called in sick after confusing Samuel L. Jackson for someone else…and then getting ripped apart for it!
Subscribe to 94.3 The Point on
KTLA reporter Sam Rubin was interviewing Jackson about his upcoming role in 'RoboCop' when he referenced Jackson's Super Bowl commercial.
Except Jackson wasn't in a Super Bowl commercial…actor Lawrence Fishburne was. (In Rubin's defense, he probably thought he saw Jackson's Capital One ad during the big game, because I see that one constantly, and it's absolutely the ad I thought he was referring to…)
Rubin apologized numerous times but Jackson wasn't having any of it, telling him, 'I'm not Lawrence Fishburne! We don't all look alike! We all may be black and famous, but we don't all look alike.'
Yep, he went there. Ah, my love for Samuel L. Jackson is deep.
Jackson went on to educate Rubin on different black actors in commercials.
Rubin kept trying to get the interview back on track, and finally about 2 minutes in, Jackson starts talking about RoboCop.
Samuel L. Jackson: Taking no s–t since 1948. Amazing.


text:
This is the transcript of a Web Conference titled Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes that took place on February 26, 2009.
Select to access the slide presentation for the Web conference (Powerpoint® slides, 4.58 MB; Text Version).
Scott Smith: Good afternoon, everybody, I am Scott Smith from the Center for Outcomes and Evidence at AHRQ [Agency for Healthcare Research and Quality], where I direct the research program for pharmaceutical outcomes. In the next 5 minutes, I am going to provide you with a very brief overview of AHRQ's Effective Health Care Program to provide some background for this presentation and also to point you to some similar resources that you can use in your practice.
The Effective Health Care Program was authorized in 2003 as part of the Medicare Modernization Act [MMA]. It began approximately 2 years later, when AHRQ actually received an appropriation of $15 million from Congress to support the work. I mentioned the MMA because the Effective Health Care Program has a special focus on health care issues facing the Medicare, Medicaid, and SCHIP [State Children's Health Insurance Program] populations, although our research is much broader.
The program is really a groundbreaking Federal effort to conduct objective, unbiased comparisons of the effectiveness of different health care interventions. We refer to this work as comparative effectiveness research or Comparative Effectiveness Reviews, and this body of work has received a great deal of attention recently with the passage of the American Recovery and Reinvestment Act, which provides expanding resources to do comparative effectiveness research for the Nation. So you will be hearing a lot about comparative effectiveness research in the upcoming months, and I suggest you stay tuned to AHRQ and to other trusted sources of information like APhA [American Pharmacists Association] so you can keep abreast of the information. But for today, the goal of this presentation is to really provide you with information about the program, which is geared toward bringing the best available scientific evidence to bear to make health care decisions.
This slide provides an organizational framework for the Effective Health Care Program. It has three major components, each of which is oriented toward supporting evidence-based practice in health care. The first component of the program is the evidence synthesis part. This involves systematic reviews and summarizing the quality of evidence found in published studies, as well as unpublished studies when they are provided by people like the manufacturers of drugs. For anyone who has done a literature search, you know what a very valuable resource this is, not only as a literature search, but because each study that meets inclusion criteria is critiqued and the body of literature is summarized to explain what is known about the balance of harms and benefits for a particular set of treatment options. And as many of you know who have done literature reviews, the quality of studies varies very widely, and so this is a huge advantage to clinicians, to have a group devoted to finding, evaluating, and summarizing the strength of evidence for a particular set of questions.
Today's presentation is one example of a systematic review. There are many more on AHRQ's Web site that I'll point to you in the future. One important part of reviewing the literature is also uncovering what is not known in a particular field, so all our systematic reviews include a section on identifying research gaps. This is also helpful to a pharmacist because he or she can communicate to patients and physicians where there is uncertainty about a particular therapy or its outcome.
So the second component of AHRQ's Effective Health Care Program is a research infrastructure that provides the ability to conduct new research to fill evidence gaps that have been identified through systematic review.
And then lastly, the third component of our program is called the Eisenberg Center, which is a center devoted to communication and translation of the reports that are produced to make them into to consumer-friendly material, including provider-friendly material and policy-friendly material.
To summarize, the program engages three primary approaches to research on comparative effectiveness. The first approach is to summarize and to synthesize the existing scientific evidence on topics that represent important clinical dilemmas for health care decisionmakers. The second approach is, where there is insufficient evidence on a topic, to generate new evidence to address those knowledge gaps. And the third is to provide meaningful information and translate those sometimes complex technical reports into plain-language guides that highlight the benefits and risks of different options, as well as the level of evidence for different therapies.
This slide shows you, from the perspective of a user, what the outputs of the program are. On the far left, I have shown the research reviews or the systematic reviews that are produced as part of the systematic review process.
The next slide shows the research reports, which are similar to journal articles, that are produced for the new research side of the program. The third products are Technical Briefs. Technical Briefs provide an overview of key issues related to an emerging clinical intervention. Technical Briefs focus on an intervention for which there is limited published data and provide an early description of an emerging area.
Most important for practitioners and pharmacists I think, are our summary guides that are derived from each of the three other products. They are in plain language and are concise ways for busy clinicians to quickly absorb the material that is produced in the research reviews and the new reports and so forth. There are summary guides for patients, there are summary guides for clinicians, and there are summary guides for policymakers.
These products can be used in a variety of ways. I will just point out a couple of them. One is they are often used to inform the development of clinical practice guidelines; they often are not the only source of information but they are one key source when guideline developers are producing guidelines. They can be used for things like coverage decisions and formulary decisions. So they are used as research products in a variety of ways.
The Agency makes a strong push to be transparent, and therefore all of the materials that we produce in the program are available on AHRQ's Web site. This slide lists the direct link to where you can look at the full reports and the summary guides. We also have audiofiles and in addition, we produce the summary guides both in English and in Spanish. So for people who are in areas where you are serving a predominantly Spanish-speaking population or have Spanish-speaking people in your patient population, we have produced the materials to accommodate the Spanish language.
If you are interested in staying in touch, we also offer the ability to push the information out to you. If you go to the Web site, you can sign up for e-mail triggers that allow you to know when new reports are produced. As soon as they are produced an e-mail goes out, you can go right on and get the new report. If there is a consumer guide that is produced, that is also pushed out through e-mail. They are very brief e-mails and, I think. valuable resources to pharmacists.
So with that, I will turn it over to the next speaker.
Barbara Bartman: Hi. Good afternoon, and good morning to those of you who are further west of us. I am going to repeat the welcome because it is my understanding that there have been some technical difficulties with sound. I want to welcome everyone to this Webinar, which is entitled Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes.
This course is being presented by the Agency for Healthcare Research and Quality's Effective Health Care Program and it is being cosponsored by the American Pharmacists Association.
My name is Barbara Bartman. I am a general internist by training and currently a medical officer at AHRQ and work with the Effective Health Care Program. I am moderating the Webinar.
This Webinar will last 60 minutes, and during this time we will hear from three speakers. You just heard from Dr. Scott Smith, who described AHRQ's Effective Health Care Program. Next you will hear from a speaker who will talk about current research on insulin analogues, and finally we will provide you with some selected suggestions as to how pharmacists can apply their research in practice.
At the end of the program, we will have a Q&A session and answer any questions that you have pertaining to the presentation. You may enter questions to the speakers at any time during the event by entering your questions in the text box in the lower left-hand side of your computer screen.
Today's event is eligible for Continuing Education [CE] credit through the Accreditation Council for Pharmacy Education with the assistance of APhA. To obtain credit, participants must attend the entire program and complete the Continuing Education registration form. We will discuss how to do this at the end of the session.
CE disclosures: As part of providing CE credit, we must provide disclosure information for all of those who participated in putting together this event. To see the disclosure information, go to the Webinar lobby Web page.
And finally, the learning objectives:
Okay, since Dr. Smith has presented, we are going to go to the second polling question before I introduce our next presenter. Our second poll question asks, "Are you currently using or planning to use AHRQ's comparative effectiveness products in your setting?
A. Yes, currently B. Yes, in the next 12 months C. Yes, in the next 12 months or later D. No"
I will read it one more time to provide you with an opportunity to answer. "Are you currently using or planning to use AHRQ's comparative effectiveness products in your setting?
A. Yes, currently B. Yes, in the next 12 months C. Yes, in the next 12 months or later D. No"
And again, please submit any questions that you may have in the text box on the lower left hand side of your screen. We will answer these during our Q&A session at the end of the Webinar.
It is now my pleasure to introduce our second speaker, Dr. Rehan Qayyum, who is the Assistant Professor of Medicine at the Johns Hopkins University School of Medicine. He was the primary investigator on this comparative effectiveness research effort, and so if it wasn't for him, it would not have been completed for the Effective Health Care Program.
Dr. Qayyum?
Dr. Rehan Qayyum: Thank you, Dr. Bartman. Hello everyone.
This report, The Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes, is based on research by the Johns Hopkins Evidence-based Practice Center under contract with the Agency for Healthcare Research and Quality.
According to data from the Centers for Disease Control and Prevention, or CDC, diabetes is the seventh leading cause of death in the United States. Patients with diabetes have a two times higher risk of death than those without diabetes and incur approximately $116 billion annually in direct medical costs. This cost is more than two times higher than patients without diabetes.
Results from large clinical trials of Type 2 diabetic patients have found that intensive control of hyperglycemia decreases mortality by 10 percent and microvascular complications such as diabetic retinopathy by 25 percent. Oral antidiabetic agents are the first line of drug for Type 2 diabetics. Once oral antidiabetic agents fail in achieving optimal control of hyperglycemia in Type 2 diabetics, insulin is commonly added to the treatment regimen. According to data from the CDC, approximately 22 percent of the U.S. Type 2 diabetics were taking insulin in 2007.
The study questions commissioned by the Agency for Healthcare Research and Quality are listed on this and next three slides. This systematic review was designed to address four key questions. First, the systematic review was to look at the effectiveness of premixed insulin analogues in comparison to other treatments for Type 2 diabetes. Second, we wanted to assess the safety, adverse effects, and adherence of premixed insulin analogues. Third, we wanted to assess the effectiveness of premixed insulin analogues in different subpopulations. And lastly, we wanted to examine their effectiveness and safety in combination with oral antidiabetic agents and in individuals with different blood glucose patterns or individuals requiring different types of blood glucose control.
Before I move on to the next slide, let me say a few words about premixed insulin analogues. These are human insulin molecules with minor structural changes. These structural changes have no impact on glucose-lowering ability of insulin, but impart important pharmacokinetic properties that allow better control of the onset and duration of insulin activity.
Premixed preparation of insulin analogues consists of mixture of rapid-acting and intermediate-acting formulations of these analogues. These premixed insulin analogues have a faster onset of action, with peak activity in about 2 1/2 hours, in a comparison to premixed human insulin preparations, which achieve peak activity in about 4 hours. There is also a faster decline in insulin activity once a peak is reached with premixed analogues.
To identify studies that addressed key questions of our study, we performed an extensive literature search. We searched electronic databases, MEDLINE, EMBASE, the Cochran Central Register of Controlled Files (or Central), and Cumulative Index to Nursing and Allied Health Literature from inception to February 2008. We also reviewed reference lists of included articles, recent issues of 30 field-specific medical journals, the Food and Drug Administration [FDA] and European Medicine's agency Web sites for the premixed insulin analogues, unpublished data from premixed analogue manufacturers, and Web sites for public registries of clinical trials, such as clinicaltrials.gov and clinicalstudyresults.org. Our aim was not to miss any public study that has addressed this topic.
We included studies that compared a premixed insulin analogue approved by FDA as of February 2008 to any other drug for adults with Type 2 diabetes and evaluated the outcomes of our interest. The outcomes included fasting glucose, postprandial glucose, and hemoglobin A1c, and we called these outcomes "Intermediate Clinical Outcomes." We also included hard critical outcomes such as all-cause mortality, cardiovascular morbidity and mortality, and microvascular outcomes such as diabetic retinopathy. We collected data on adverse events such as hypoglycemia and weight gain. Data on quality of life were abstracted if reported. We included randomized controlled trials, controlled clinical trials, and observational studies with control groups regardless of the duration of followup or sample size. We did not include results for hemoglobin A1c in our trial if the duration of followup was less than 12 weeks in that trial, for obvious reasons. We also did not include the results of progressive outcomes from crossover trials.
Two investigators reviewed the titles, abstracts, and full articles independently for inclusion and abstracted data by using standardized forms. For intermediate outcomes and adverse effects, we pooled the results of individual studies using a random effects model. For clinical outcomes, we included all studies that reported any information about clinical events such as all-cause mortality, and cardiovascular mortality and morbidity.
All analysis followed the Intention to Treat principle. While many studies did not report on hard clinical outcomes, few studies that reported these outcomes had very few events. The presence of real events in pooling data makes any single method unreliable. We therefore used several different statistical approaches to confirm the robustness of our results.
We classified evidence pertaining to key questions into three basic categories: "high-grade" evidence indicating confidence that further research is very unlikely to change our confidence in estimated effects; "moderate-grade" evidence indicating that further research may have an important impact on our confidence in the estimates of effects; and "low-grade" evidence indicating that further research is very likely to have an important impact on the confidence in the estimates of effects and is likely to change the estimates from our study. We graded the evidence as "no evidence" if there were no studies evaluating the drug comparison.
And here I will be presenting results. Our literature search found 45 studies that reported on at least one of the intermediate clinical outcomes on all adverse events. All were randomized controlled trials except two. In two of these studies, patients were enrolled consecutively. In one of these two studies, patients were enrolled consecutively and followed prospectively, while in the other study, data were obtained from the medical records database of a large employer.
Among the randomized controlled trials, 23 were parallel-armed and 20 were crossover trials. The median duration of followup in these trials was 16 weeks, with a range of 1 day to 2 years. Median age of patients in these studies was 59 years, and approximately 52 percent of the subjects were males.
This slide shows a forest plot, and it compares the fasting glucose-lowering effect of premixed analogues with other agents. The left-hand side of the figure lists the name of competitors and the premixed analogue to which it is compared. The middle part of the figure gives the weighted mean difference of fasting blood glucose of each comparison with 95-percent confidence in results in a graphic form, and numerical values are on the right-hand side of the figure. The upper third of the figure shows that long-acting insulin analogues are clearly better than premixed insulin analogues in lowering fasting glucose. The difference was about 12 milligrams per deciliter between long-acting analogues and premixed analogues combined, and ranged from 6.4 milligrams per deciliter for Insulin Aspart 70/30 to 24.7 milligrams per deciliter for Insulin Lispro 50/50.
The middle part of the figure compares premixed human insulin preparation with premixed analogues. Overall, premixed human preparations seem to be better than premixed analogues, although 95-percent confidence intervals crossed midline. In contrast, the lower third of the figure shows that premixed insulin analogues were significantly better than noninsulin antidiabetic agents in lowering fasting glucose.
This forest plot displays results for postprandial glucose. Most studies reported glucose levels 2 hours after meals, but some studies reported results 90 minutes after meals. For this analysis we pooled data from these two types of studies. As compared to fasting glucose, which was shown in the previous figure, premixed insulin analogues were clearly superior to long-acting insulin analogues, premixed human insulin, and noninsulin antidiabetic agents in lowering postprandial glucose. This is consistent with what one would expect based on the faster onset effect of these premixed analogues.
Hemoglobin A1c is the most commonly used clinical measure to follow glucose control in diabetic patients. It assesses average glucose levels that body is exposed to over the 12-week period prior to the test. Premixed insulin analogues were similar to premixed human insulin in lowering A1c. In contrast, premixed analogues were superior to long-acting insulin analogues and noninsulin antidiabetic agents in lowering A1c, and the lowering effect was an additional one-half percentage point.
However, these results can be due to the underlying study designs. In several studies, the total daily dose of long-acting insulin analogues was less than the premixed insulin analogues dose, and this difference may have resulted in the observed benefit of premixed analogues. Similarly, in several studies the dose of noninsulin antidiabetic agents was fixed throughout the study, while the dose of premixed analogues was allowed to be adjusted to optimize glucose control. This difference may have resulted in the findings on this slide.
Hypoglycemia is an important adverse outcome, and Type 2 diabetic patients on insulin are at risk of this adverse event. The left side of this forest plot is different from the previous plot. Instead of listing individual premixed analogues, it lists different grades of hypoglycemia. Overall, long-acting insulin analogues and noninsulin antidiabetic agents appear to be better than premixed insulin analogues in reducing the risk of hypoglycemia. Premixed insulin analogues appear to have risks of hypoglycemia which are similar to premixed human insulin preparations.
This slide shows the results for weight gain. There were little data on the effect of premixed analogues on weight change as compared to other agents. Patients using long-acting insulin analogues and noninsulin antidiabetic agents had smaller weight gain as compared to patients using premixed analogues. However, this difference could be due to the lower dose of long-acting insulin analogues as compared to premixed analogues dose and due to the use of [inaudible] in several studies of noninsulin antidiabetic agents. There were insufficient data on the comparison of premixed analogues with premixed human insulin. Only two studies comparing Insulin Aspart 70/30 with premixed human insulin reported weight change. The results were not statistically significant in one study and the second study did not report statistical significance or provide sufficient data.
There were very little data on other comparisons. We found only two studies that compared a premixed analogue with a rapid-acting insulin analogue; two studies that compared a premixed analogue with a combination regimen of long-acting and rapid-acting insulin analogue, also known as basal-bolus regimen; two studies that compared a premixed insulin analogue to intermediate-acting insulin; and one study that compared a premixed analogue with a combination of rapid-acting analogue with intermediate-acting human insulin. Due to sparseness of the data, we were unable to draw firm conclusions about these comparisons.
Moving on to clinical outcomes—there were very few data for individual comparisons, and as before, we combined all premixed analogues into one group and comparators into the other group. Although we did not find statistically significant differences between premixed analogues and the competitors in terms of all-cause mortality, cardiovascular mortality, or cardiovascular morbidity, looking at this forest plot, a suggestion of harm can be seen in the pooled-up chances for all outcomes except cardiovascular morbidity. However, these point estimates were based on few absolute events in only a few studies in which clinical outcomes were not the primary end point. Data from future studies may change our conclusions. For microvascular outcomes, we found insufficient or no evidence.
As compared with premixed human insulin that needs to be given about 30 minutes before meals, premixed insulin analogues can be given with meals. This flexibility may improve the overall quality of life. We found only six studies that evaluated quality of life. Of these six, only four studies used a validated quality-of-life scale. In one of these four studies, there were some differences between the premixed insulin analogue and its competitor. This study assessed six quality-of-life measures; only one—psychological distress—showed a statistically significant difference favoring premixed insulin analogues over oral antidiabetic agents. Thus we cannot draw firm conclusions regarding quality-of-life outcomes for any comparison.
We also collected data from the studies that compare patients taking combinations of premixed insulin analogues and oral antidiabetic agents with patients taking only premixed insulin analogues. In the small number of studies evaluating this comparison, there was no difference between the two treatments in fasting and postprandial glucose, incidence of hypoglycemia, weight change, or clinical outcomes. However, we found that combination of premixed analogues and oral antidiabetic agents was better in lowering A1c than premixed analogues alone.
We did not find any evidence on adherence to treatment regimen or effectiveness and safety of premixed analogues in subpopulations of interest as outlined in our key questions; in individuals with different intensity of glucose control; and in targeting fasting versus postprandial glucose control.
This slide summarizes most outcomes by comparison. Upward arrows mean that insulin at the top of the column is better than premixed analogues. Downward arrows mean otherwise. Horizontal arrows mean that both are similar. An "X" in the field means that there are no data on that comparison.
In summary, when compared to long-acting insulin analogues, we found that premixed analogues are better in lowering A1c and postprandial glucose, but less effective in lowering fasting glucose. Premixed analogues are similar to premixed human insulin in lowering fasting glucose and A1c, but better in lowering postprandial glucose. Risk of hypoglycemia with premixed analogues is similar to premixed human insulin, but hypoglycemia risk is higher when compared to long-acting insulin analogues.
The major gap in evidence that we noticed was that our search did not find any study that was specifically designed to evaluate hard clinical outcomes. The few studies that reported clinical outcomes were of relatively short duration and were neither designed nor powered to assess clinical outcomes. We also did not find sufficient data on quality of life or adherence to treatment regimen.
In conclusion, based on the findings of this systematic review, we recommend that therapy should be individualized. In the presence of elevated hemoglobin A1c, premixed insulin analogues seem better than long-acting insulin analogues and oral antidiabetic drugs. There does not appear to be any difference between premixed analogues and premixed human insulin in preparations.
In patients with fasting hyperglycemia, long-acting insulin analogues seem to be a better choice than premixed analogues. In patients with postprandial hypoglycemia, premixed insulin analogues seem preferable to long-acting analogues, premixed human insulin, or oral antidiabetic agents. If risk of hypoglycemia is a major concern, then long-acting insulin analogues seem to have much lower risk of hypoglycemia than premixed insulin analogues. There does not appear to be any difference between premixed analogues and premixed human insulin.
This is the list of investigators who contributed to this study in a significant manner. Thank you, and I will go back to Dr. Bartman.
Barbara Bartman: Thank you very much, Dr. Qayyum. Greatly appreciate it, that was a great study that you did.
As I mentioned previously, Dr. Carmen Kelly, who is a pharmacist at the Agency ,was going to provide you with some information on the utility and value of the systematic review. However, she is sick today, so I basically am going to take some of her notes and her information and discuss with you some practical applications of the systematic review.
I think, as you can discern from the systematic review, there still are a lot of questions that need to be answered. What I would like to do is discuss a few in the next several minutes, some of the "real world" applications or the value and utility of the research that has just been presented.
As you likely gleaned from the discussion, to really implement practice changes the results of this research require further confirmation. We need more studies; in some cases, studies that haven't even been done yet. However, it is possible to still consider the utility and value of the systematic review for an individual pharmacist, for further pharmaco-epidemiologic research, and also for education.
First, I would like to discuss the implications for practice. There are many findings—I could go on and on about the number of implications for practice—however, we have been selective in choosing which ones we would talk about, or perhaps recommend. Given that there are now a multitude of insulin preparations available on the market and the potential need for frequent changes in patients and their dosages, pharmacists must be able to ensure that patients adhere to their insulin regimen, their diet, that they are consistent in their activities. These are all necessary to maintain an acceptable glucose level and to avoid hypoglycemia and weight gain. Based on the results of the systematic review, it would seem reasonable for a pharmacist or provider to continue a patient on a regimen of premixed human insulin that they have been on or a basal analogue regimen if they have been responding appropriately (i.e., their hemoglobin A1c levels are within an acceptable range and they are not experiencing any side effects).
The change to premixed insulin analogues would seem like an acceptable alternative if individuals are having difficulty controlling their postprandial blood sugar levels but not fasting sugar levels (i.e., their hemoglobin A1c levels are high despite acceptable or unacceptable fasting levels and high postprandial levels).
It is necessary and important to ensure that patients make informed choices about their treatment, because only they know about what they can tolerate, what they can afford. If cost is an issue, then patients may elect to cover themselves with regular human insulin after meals. It may be the only realistic treatment or option for them. And of course, in regard to safety, one must always be cognizant of the risk of hypoglycemia and monitoring of blood sugar levels as well as weight gain.
In terms of implications for research, the studies used in this systematic review were largely studies with efficacy (i.e., the studies were done under ideal conditions). Ultimately, to truly understand the benefit of the premixed insulin analogues in the population, comparative effectiveness research will be necessary to further our knowledge about which therapies work best for which individuals—i.e., do certain subgroups benefit more than others: the old, the young, individuals of different gender, race, ethnicity, disease severity, and those with comorbid conditions?
Many questions cannot be answered in this systematic review because there were not enough efficacy studies to be examined in a systematic way. These in particular include examining basal-bolus therapy, a regimen where a long-acting insulin analogue is used with a rapid-acting analogue against the standard treatment.
In addition, studies need to be of longer duration to really understand the sustained effect of treatment with these newer agents compared with human insulin, especially in long-term clinical outcomes such as coronary disease, nephropathy, and retinopathy, and not just laboratory values such as fasting sugars, postprandial glucose levels, and hemoglobin A1c's.
Knowledge about the research that has been done on these new insulins is necessary to be able to answer patients' questions about them. Pharmacists, even more importantly, need to be able to discuss with the physician when it is best to start a patient on premixed insulin analogues.
As the review shows, there is no significant difference between human insulin and premixed analogues on fasting blood sugar levels. Based on this finding, a patient doing well on human premixed insulin may not necessarily benefit from a change to a premixed preparation. However an individual who is experiencing poor control on a regimen with basal analogues or human insulin and has high hemoglobin A1c's may benefit from a change. Such information is useful in a physician consultation if a drug change is considered. Ultimately, we want to be able to educate patients about their insulin regimens and also discuss with health care providers the best therapy for their patients.
Okay, we are now going to take online questions related to our speakers' presentations. If you would like to ask a question, please type it in the text box on the lower left-hand side of your computer screens.
Where can I get a copy of the report? That's a very important question, which we will get into a little bit later. These slides will be posted online within 2 business days on the registration Web site and soon after on our EHC Web site, so stay tuned.
Rehan, is there evidence of titration of different insulin preparations?
Rehan Qayyum: Studies that we looked at did not study titration to different insulin preparations. If I understand the question correctly, what is being asked is about switching from one insulin preparation to another insulin preparation? And so none of the studies we looked at was actually looking at this particular question. When we were doing our search, we did find a few observational studies that were done in this way, but first they did not fulfill our inclusion criteria, and second the study quality in each of those observational studies was really low and so it is very difficult to have any conclusion drawn from any of those studies.
Barbara Bartman: Thank you. It looks like we are running low on time, so I am going to ask Scott one more question. Are there any materials that I may provide my patients such as a consumer guide? If so, where are the materials available?
Scott Smith: Thank you, Barbara. So all of the materials are available on AHRQ's Effective Health Care Web site. That is effectivehealthcare.ahrq.gov. There are consumer guides related to this report as well as other reports that are downloadable in pdf format. You are also able to order them in printed format from AHRQ's Clearinghouse, and that information is available on the slide presentation.
The full report written by the Johns Hopkins Evidence-based Practice Center is available today on AHRQ's Web site; you can download that if you are also interested in seeing the full report. It was also copublished in the Annals of Internal Medicine, and so you can see it from Annals as well.
Barbara Bartman: Great. If you have any other question after the Webinar, please email us at email@example.com. This will be on the slide presentation as well.
A few logistics as well before we wrap up: In terms of obtaining CE credit, please visit www.pharmacists.com by March 13, 2009, and enter the verification code provided on the slide before you: DCI226. You will receive a feedback form at this Webinar to provide us with your input. We really ask and please need your time to complete this form; it would be very helpful for us.
Again, thank you for joining us today. We hope despite the technical difficulties—and I am sure many of you can sympathize with our experience—we all hope that you join us again on May 1st for our second Webinar, which will be entitled Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. This is based on an article just published in the New England Journal of Medicine. We will send everyone an e-mail with the Web site and instructions for this Webinar.
Thank you, and that concludes our Webinar today. If you would like to submit any questions, again please e-mail us at email@example.com. You can also use this e-mail address to nominate topics for future Effective Health Care reports if there is something of interest to you in the field of diabetes or any other topic.
And as I mentioned previously, the presentation slides will be posted online on the registration Web site within 2 business days, and soon after on our Effective Health Care Web site. This concludes today's Webinar. Thank you all speakers and everybody who helped put this together.
Return to Contents


text:
Hi guys
when i checked out Backtrack for the first time a few months ago, there was an awesome free backtrack course somewhere on the interwebs, I think it might have even been hosted by offensive security.
has that course disappeared? I can't seem to find it via google or the backtrack site (which should def link to it, if it still exists somewhere).
Thanks for the help!
proud user of backtrack-ng and aircrack-linux
Ah, yes, thanks. It was 'Metasploit Unleashed' I was thinking of. Googleing for Backtrack obviously didn't take me back there and the MSFU link on Offensive Security is pretty hidden
I thought it explained more of backtrack's tools, but no'pe.


text: Daughter of Samuel Chamberlain (1788-1865) and Mercy Cotton (1792-1880), of Cayuga Co., NY. In 1848, she married Abram G. Bodine in Huron Co., OH. Children: Ada O.; Frank Chamberlain; and Laura Augusta (Laurie). Some sources give her name as "Cordelia Mercy" or "Mary Cordelia." Her date of birth is sometimes listed as 1824.


text:
Strong earthquake in Iran: At least 10 dead, four villages destroyed
A powerful earthquake measuring 5.9 on the Richter scale hit Iran's southern coastline on Sunday, state media said. IRNA said the epicentre of the quake, which was occurred at 1:52 pm (1023 GMT), was near the Gulf island of Qeshm, around 35 kilometres from the port city of Bandar Abbas.
The quake was felt for more than 10 seconds. Terrified people ran out of their homes and rushed to the streets to save their lives, IRNA added. The villages of Tonban, Gourian, Goursin and Khaldin were reported to be completely destroyed, according to the governor of Qeshm, Heydar Alishvandi.
At least 10 people were killed and dozens of others were wounded, the official said, adding relief workers were immediately dispatched to the affected areas. IRNA reporter said that the only hospital in the city, which lacked basic medical facilities, was full of injured people. Local officials met at the governor's office to set up an emergency task force to rush relief to the victims.
Quakes of varying magnitudes often occur in Iran, which is situated on some of the world's most active seismic fault lines.
It should be noted that Sunday's earthquake was also felt in the UAE. One Dubai resident told Albawaba that the prestigious Emirates Towers complex, which is located on the Sheikh Zayed road in Dubai, was evacuated.
© 2005 Al Bawaba (www.albawaba.com)


text:
J. graduated middle school yesterday with an awards ceremony last night, graduation dance at the school and {can you believe this?} poolside after-party at the house of one of their fellow graduates. Crazy. And apparently exhausting. He's currently skipping most of his last day of school today and "sleeping it off" deep into the morning (all that pop and chips and midnight swimming really takes it out of a buddy); I expect he'll wake up in time to clear out his locker and the head to the next party, an end-of-year celebration being thrown by another graduate. Holy cow.
I hadn't realized grade 8 grad was such a big deal, but evidently, it's huge. Most of the kids will be moving on to a new high school that's opening this September; they'll be the first students to attend. A small handful - J. among them - will attend a smaller, established high school on the other side of town. (Point of interest? It's the same high school I attended, and my mum and her brothers before me: the benefits of a small town.) Old relationships will be forgotten; new relationships will be formed. His social construct will change dramatically over the next few months, in ways he can't even begin to imagine, and though he doesn't realize it, it's begun already. His world is changing ~ he's changing ~ and last night brought him one step closer.
Adios, middle school. Thanks for the memories, grade 8. It's been a slice.
|J. (on the right) and his buddy L.
|The boy and his proud parents
|J. and his grandmother (my mum)
L-R: Matthew (my brother), me, J., Mum {or 'Grimmy', as the kids call her), Daryn


text:
Hey there! We are Venture Ventura — a group of recent college graduates, young professionals, civil servants, outsdoorsmen, artists, home brewers, and current residents of Ventura County. We've created this site to bring events, businesses and fun to like-minded individuals in Ventura County.
Our mission is to facilitate connection in Ventura County, build awareness of community, and curate all things local.
Do you share a passion for having fun in Ventura County? Are you interested in contributing to, or even joining, our team? We'd be happy to talk to you! Reach out to us via social media or send us an email using our contact form!